Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | CFO and Treasurer | November 20, 2017 | November 20, 2017 |
| Protalix BioTherapeutics, Inc.PLX · Entity 2671 | Sr. VP and CFO | September 23, 2024 | November 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date November 20, 2017 · Filed November 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
After 2017-11-20 transaction · row 1
1 source rowRow 1 · 2017-11-20 · Grant · Acquired 25,000 · Balance 25,000 F1: Shares acquired are shares of restricted stock awarded on November 20, 2017 under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 100% of the award on April 1, 2018, provided that the Reporting Person remains continuously employed by Brainstorm Cell Therapeutics Ltd. from the date of grant through the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2027-11-20 | Direct | 93,686 |
Reported balance
After 2017-11-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-11-20 · Grant · Acquired 93,686 · Balance 93,686 F2: Option shall vest and become exercisable as to 25% of the underlying shares on each of the first, second, third and fourth anniversary of the date of grant, until fully vested and exercisable on the fourth anniversary of the date of grant, provided Reporting Person remains employed by Brainstorm Cell Therapeutics Ltd. from the date of grant through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired are shares of restricted stock awarded on November 20, 2017 under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 100% of the award on April 1, 2018, provided that the Reporting Person remains continuously employed by Brainstorm Cell Therapeutics Ltd. from the date of grant through the vesting date.
F2: Option shall vest and become exercisable as to 25% of the underlying shares on each of the first, second, third and fourth anniversary of the date of grant, until fully vested and exercisable on the fourth anniversary of the date of grant, provided Reporting Person remains employed by Brainstorm Cell Therapeutics Ltd. from the date of grant through each applicable vesting date.
Protalix BioTherapeutics, Inc.
Report date September 23, 2024 · Filed November 05, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 660,909 |
Reported balance
After 2024-09-23 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-09-23 · Grant · Acquired 90,909 · Balance 660,909 F1: The original Form 4, filed on September 24, 2024, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the amount of restricted shares granted. F2: Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended. F3: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The original Form 4, filed on September 24, 2024, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the amount of restricted shares granted.
F2: Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended.
F3: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Nasus Pharma Ltd
Report date September 18, 2026 · Filed September 21, 2026
Section 16 reporting ended · disclosed 2026-09-21. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2024 Filed Sep 24, 2024 21:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 99,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-023907 · form4-09242024_050905.xml · nonDerivative · entry 1 Rubin Eyal · CIK 0001721411 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 669,010 F1 · price: Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended. F2 · ownership.direct: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. Read SEC document |
| September 23, 2024 Filed Nov 5, 2024 22:00 UTC Amendment | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 90,909 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-026168 · form4a-11052024_051110.xml · nonDerivative · entry 1 Rubin Eyal · CIK 0001721411 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 660,909 F1 · security: The original Form 4, filed on September 24, 2024, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the amount of restricted shares granted. F2 · price: Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended. F3 · ownership.direct: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:30 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 201,903 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-093070 · tm2324046-3_4seq1.xml · nonDerivative · entry 1 Rubin Eyal · CIK 0001721411 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 570,000 F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan. F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 21:03 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001104659-22-098950 · tm2225460-7_4seq1.xml · derivative · entry 1 Rubin Eyal · CIK 0001721411 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2032-09-07 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. F2 · balance_after: Does not include options to purchase 80,000 shares of common stock at an exercise price equal to $2.00 per share that expire on September 22, 2029. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:02 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 121,951 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-028159 · tm227910-2_4seq1.xml · nonDerivative · entry 1 Rubin Eyal · CIK 0001721411 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 368,097 F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020. F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 21:03 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 246,146 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-094755 · tm2027548d3_4.xml · nonDerivative · entry 1 Rubin Eyal · CIK 0001721411 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 246,146 F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the "Plan"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan. F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. Read SEC document |
| August 11, 2020 Filed Aug 14, 2020 21:01 UTC Amendment | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 246,146 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-095626 · tm2027654-2_4a.xml · nonDerivative · entry 1 Rubin Eyal · CIK 0001721411 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 246,146 F1 · security: The original Form 4, filed on August 13, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the vesting schedule of the restricted shares. F2 · security: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the "Plan"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan. F2 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the "Plan"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan. F3 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. Read SEC document |
| September 22, 2019 Filed Sep 24, 2019 21:01 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 800,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001144204-19-045806 · tv530009_4.xml · derivative · entry 1 Rubin Eyal · CIK 0001721411 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2029-09-22 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended. Read SEC document |
| November 20, 2017 Filed Nov 20, 2017 21:26 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (right to buy) · Derivative | 93,686 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001144204-17-060168 · tv478601_4.xml · derivative · entry 2 Rubin Eyal · CIK 0001721411 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,686 Underlying: Common Stock · 93,686 shares Expires 2027-11-20 F2 · derivative.exercise_date: Option shall vest and become exercisable as to 25% of the underlying shares on each of the first, second, third and fourth anniversary of the date of grant, until fully vested and exercisable on the fourth anniversary of the date of grant, provided Reporting Person remains employed by Brainstorm Cell Therapeutics Ltd. from the date of grant through each applicable vesting date. Read SEC document |
| November 20, 2017 Filed Nov 20, 2017 21:26 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-060168 · tv478601_4.xml · nonDerivative · entry 1 Rubin Eyal · CIK 0001721411 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Shares acquired are shares of restricted stock awarded on November 20, 2017 under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 100% of the award on April 1, 2018, provided that the Reporting Person remains continuously employed by Brainstorm Cell Therapeutics Ltd. from the date of grant through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.